Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy

Journal of Biomaterials Science, Polymer Edition

Volumn 26, Issue 13, 2015, Pages 813-827

  Li, Manhong ^a   Li, Yong ^a   Huang, Xiaohui ^a   Lu, Xizhi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Anti angiogenesis; Breast cancer; Captopril; Gold nanoparticles; SiRNA

Indexed keywords

AMIDES; CONTROLLED DRUG DELIVERY; DISEASES; FIBER OPTIC SENSORS; GENES; GOLD NANOPARTICLES; MAMMALS; METAL NANOPARTICLES; ONCOLOGY; PARTICLE SIZE; TARGETED DRUG DELIVERY; TUMORS;

ANGIOGENESIS; ANTI-TUMOR ACTIVITIES; BREAST CANCER; CAPTOPRIL; LOW MOLECULAR WEIGHT; SIMULTANEOUS TRANSFER; SIRNA; VASCULAR ENDOTHELIAL GROWTH FACTOR;

GOLD COMPOUNDS;

CAPTOPRIL; GOLD NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; DRUG CARRIER; GOLD DERIVATIVE; MESSENGER RNA; METAL NANOPARTICLE; VASCULOTROPIN A;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; GENE DELIVERY SYSTEM; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; RNAI THERAPEUTICS; TUMOR CELL LINE;

MUS MUSCULUS;

ANGIOGENESIS INHIBITORS; ANIMALS; CAPTOPRIL; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; FEMALE; GENE SILENCING; GOLD COMPOUNDS; MAMMARY NEOPLASMS, EXPERIMENTAL; METAL NANOPARTICLES; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; POLYETHYLENEIMINE; RNA, MESSENGER; RNA, SMALL INTERFERING; RNAI THERAPEUTICS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84937853473     PISSN: 09205063     EISSN: 15685624     Source Type: Journal    
DOI: 10.1080/09205063.2015.1057991     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA-Cancer J. Clin. 2012; 62: 10-29.
2. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006; 127: 679-695
3. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010; 28: 341-347
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249-257
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995; 1: 27-30
6. Mayer RJ. Two steps forward in the treatment of colorectal cancer. New Engl. J. Med. 2004; 350: 2406-2408
7. Meng H, Xing G, Sun B, et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano. 2010; 4: 2773-2783
8. Murata N, Takashima Y, Toyoshima K, et al. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Release. 2008; 126: 246-254
9. Ferrara N, Hillan KJ, Gerber H-P, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004; 3: 391-400. 10.1038/nrd1381
10. Kim SH, Jeong JH, Lee SH, et al. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release. 2006; 116: 123-129
11. Amaral SL, Papanek PE, Greene AS. Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training. Am. J. Physiol. Heart Circ. Physiol. 2001; 281: A614.
12. Higgins RD, Yan Y, Geng Y, et al. Captopril and vascular endothelial growth factor in a mouse model of retinopathy. Curr. Eye Res. 2003; 27: 123-129
13. Kowala MC, Valentine M, Recce R, et al. Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril. J. Cardiovasc. Pharm. 1998; 32: 29-38
14. Lewis DL, Hagstrom JE, Loomis AG, et al. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 2002; 32: 107-108
15. Martinez J, Patkaniowska A, Urlaub H, et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002; 110: 563-574
16. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003; 55: 329-347
17. Wang Y, Gao S, Ye W-H, et al. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mat. 2006; 5: 791-796
18. Novo L, Rizzo LY, Golombek SK, et al. Decationized polyplexes as stable and safe carrier systems for improved biodistribution in systemic gene therapy. J. Control. Release. 2014; 195: 162-175
19. Grayson ACR, Doody AM, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharmaceut. Res. 2006; 23: 1868-1876
20. Wang C, Bao X, Ding X, et al. A multifunctional self-dissociative polyethyleneimine derivative coating polymer for enhancing the gene transfection efficiency of DNA/polyethyleneimine polyplexes in vitro and in vivo. Polym. Chem. 2015; 6: 780-796
21. Connor EE, Mwamuka J, Gole A, et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005; 1: 325-327
22. Ghosh P, Han G, De M, et al. Gold nanoparticles in delivery applications. Adv. Drug Deliv. Rev. 2008; 60: 1307-1315
23. Bao X, Wang W, Wang C, et al. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy. Biomaterials. 2014; 35: 8450-8466
24. Lee SH, Bae KH, Kim SH, et al. Amine-functionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers. Int. J. Pharm. 2008; 364: 94-101
25. Liu Y, Shipton MK, Ryan J, et al. Synthesis, stability, and cellular internalization of gold nanoparticles containing mixed peptide-poly (ethylene glycol) monolayers. Anal. Chem. 2007; 79: 2221-2229
26. Liu J, Jiang X, Xu L, et al. Novel reduction-responsive cross-linked polyethylenimine derivatives by click chemistry for nonviral gene delivery. Bioconjugate Chem. 2010; 21: 1827-1835
27. Limbach LK, Li Y, Grass RN, et al. Oxide nanoparticle uptake in human lung fibroblasts: effects of particle size, agglomeration, and diffusion at low concentrations. Environ. Sci. Technol. 2005; 39: 9370-9376.
28. Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release. 2006; 114: 100-109
29. Lee M, Nah J-W, Kwon Y, et al. Water-soluble and low molecular weight chitosan-based plasmid DNA delivery. Pharm. Res. 2001; 18: 427-431
30. Amaya K, Ohta T, Kitagawa H, et al. Angiotensin II activates MAP kinase and NF-B through angiotensin II type I receptor in human pancreatic cancer cells. Int. J. Oncol. 2004; 25: 849-856.
31. Anandanadesan R, Gong Q, Chipitsyna G, et al. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J. Gastrointest. Surg. 2008; 12: 57-66
32. Takei Y, Kadomatsu K, Yuzawa Y, et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004; 64: 3365-3370
33. Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin. Cancer Res. 2006; 12: 2888-2893